Hepatitis and HIV

Topics in this section

Hepatitis and HIV: latest news

Hepatitis and HIV resources

  • Hepatitis B

    Hepatitis B is a virus that can cause serious or even fatal damage to the liver. In countries like the UK, hepatitis B is usually...

    From:Factsheets

  • Hepatitis C

    Hepatitis C virus was first identified in the 1980s. Although it is not related to other hepatitis viruses, it can cause similar symptoms. It is...

    From:Factsheets

  • Liver function tests

    You'll have a number of routine tests to monitor your health as part of your HIV care. Tests are also used to see if you...

    From:Factsheets

  • The liver

    The liver is the largest organ in the human body and is situated in the upper right-hand side of the abdomen (tummy), protected by the...

    From:Factsheets

  • Hepatitis C

    Information on hepatitis C, including transmission, treatment and interactions with HIV and anti-HIV treatment....

    From:HIV treatments directory

  • Hepatitis C virus treatment

    The current preferred treatment regimen for HCV infection is a combination of peginterferon alfa (given by injection) plus ribavirin (given orally). Interferons are human proteins that...

    From:HIV treatments directory

  • HIV & hepatitis

    This booklet gives information for people with HIV who also have hepatitis A, hepatitis B or hepatitis C....

    From:Booklets

  • Non-HIV-related illnesses – hepatitis

    Co-infection with hepatitis B virus or/and hepatitis C virus is increasingly becoming a cause of illness in people with HIV. Both these viruses affect the liver,...

    From:namlife.org

Hepatitis and HIV features

Hepatitis and HIV in your own words

Hepatitis and HIV news from aidsmap

More news

Hepatitis and HIV news selected from other sources

  • Gilead, Vertex and the Mystery of Missing Hep C Patients

    Why is everyone obsessed with hepatitis C? Since the early 1990s, routine screening of donated blood has drastically reduced the incidence of new HCV cases; there is no ongoing epidemic of new infections to explain the excitement. Moreover, successful HCV treatment leaves patients cured, and cured patients don't need expensive drugs. Yet despite these dynamics, drug companies large and small are spending hundreds of millions of dollars seeking new HCV drugs; investors are rewarding these efforts with multi-billion-dollar market valuations.

    22 hours ago | The Street

  • Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

    The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)-boosted protease inhibitor (PI) combinations, according to preliminary data from a clinical trial and a warning issued to health care providers by Merck on February 6. 

    08 February 2012 | AIDSMeds

  • European Study Does Not See Rapid Long-Term Liver Fibrosis in HIV/HCV Coinfected People

    People who are already HIV positive when they acquire hepatitis C virus (HCV) may not experience unusually rapid liver disease progression over the long term, even though the fibrosis progression rate may appear high during the acute stage of infection, according to a European FibroScan study described in the February 15, 2012, issue of Clinical Infectious Diseases.

    02 February 2012 | HIVandHepatitis.com

  • Statins May Stave Off Liver Cancer in People With Hepatitis B

    Study found lower risk of developing disease for people taking these cholesterol-cutting drugs

    30 January 2012 | Health Day

  • More must be done to reduce hepatitis C transmission amongst HIV positive gay men

    The rate of HIV-positive gay men co-infected with hepatitis C in the UK is too high. It is crucial for this to be addressed as a strategic priority in gay men's health promotion. 

    30 January 2012 | NAT

  • Entry Point for Hepatitis C Infection Identified

    A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of Illinois at Chicago College of Medicine.

    25 January 2012 | University of Illinois press release

  • Hepatitis C vaccine: Oxford researchers' trial 'promising'

    An early clinical trial of a hepatitis C vaccine has shown "promising" results, according to researchers at Oxford University.

    04 January 2012 | BBC

  • Top 10 HIV and Hepatitis Stories of 2011

    In our last issue for 2011, HIVandHepatitis.com reviews some the year's major news highlights.

    03 January 2012 | HIVandHepatitis.com

  • AASLD: High Sustained Response Rates with Danoprevir plus Pegylated Interferon/Ribavirin for HCV

    The hepatitis C virus (HCV) NS3/4A protease inhibitor danoprevir (formerly RG7128) plus pegylated interferon/ribavirin produced high cure rates and many patients were eligible for shorter therapy, according to findings presented at the recent American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.

    12 December 2011 | HIVandHepatitis.com

  • Poor Liver Transplant Outcomes for HIV/HCV Coinfected Patients

    Patients coinfected with hepatitis C virus (HCV) and HIV have only a 55% chance of survival 5 years after liver transplantation, according to results from a study performed at a French transplant center.

    06 December 2011 | Medscape (requires free registration)
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also